PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo; Representative Director: Jun Minamitani; hereinafter referred to as "the Company") has succeeded in developing a special peptide, "PDGF-AA Substitute Peptide [Product Code: PG-014]", which has the same function as Platelet-derived growth factor (PDGF)-AA, and will commence sales in July 2026. Background of PG Peptide Development Growth factors, cytokines, etc., used in the manufacturing of regenerative medicine and cell therapy products, face challenges such as potential variations in quality between manufacturing lots, safety concerns due to contamination with animal-derived components, stability concerns, and high market prices leading to cost issues when used in large quantities. The Company was established in April 2020 as a joint venture between Mitsubishi Corporation and Peptro Dream Inc. with the mission to solve these challenges and contribute to the further dissemination and expansion of regenerative medicine and cell therapy. Since its establishment, based on a joint development agreement with Peptro Dream Inc., the Company has been developing special peptides (PG peptides) that have the same functions as dozens of growth factors and cytokines, and are fully chemically synthesizable. About PDGF-AA Substitute Peptide [Product Code: PG-014] ➢ Mechanism of PDGF-AA Substitute Peptide's PDGF Receptor $\alpha$ Activation The PDGF-AA Substitute Peptide (PG-014) is a homodimer peptide composed of cyclic peptides that bind to PDGF receptor $\alpha$ (PDGFR$\\alpha$). Similar to PDGF-AA, it exhibits agonist activity by inducing homodimerization of PDGFR$\\alpha$ (Figure 1). Figure 1 Conceptual Diagram of PG-014's Mechanism of Action ➢ Signal Activation and Cell Proliferation Activity Similar to Recombinant PDGF-AA Figure 2 PDGFR$\\alpha$ Phosphorylation Test Results Figure 3 Survival Test Results of Ba/F3 Cells with Constitutive PDGFR$\\alpha$ Expression A comparative study of the functions of PG-014 and commercially